Nasal airway dysfunction — encompassing allergic rhinitis, non-allergic rhinitis, chronic rhinosinusitis, and nasal polyps — affects 30–40% of the population and represents a significant driver of sleep-disordered breathing, asthma exacerbations, work productivity loss, and quality of life impairment. Despite being one of the most common conditions in ambulatory medicine, rhinitis is frequently undertreated with antihistamines when evidence-based first-line therapy (intranasal corticosteroids) would be more effective.
Allergic vs. Non-Allergic Rhinitis and Treatment
Allergic rhinitis (IgE-mediated, triggered by environmental allergens): 20% prevalence. Seasonal (SAR) versus perennial (PAR) — distinction important for treatment timing. First-line: intranasal corticosteroids (INS). Meta-analysis evidence: INS (fluticasone, mometasone, budesonide) significantly superior to oral antihistamines for nasal congestion (the most impactful symptom) and for total nasal symptom scores — and comparable for sneezing/rhinorrhea. INS + antihistamine combination superior to either alone for total symptom relief in moderate-severe SAR. Allergen immunotherapy (AIT): subcutaneous (SCIT) or sublingual (SLIT) provides disease-modifying benefit — reduces allergen sensitivity over years of treatment, reduces new sensitizations, and has preventive effect on asthma development. The only evidence-based treatment that modifies the underlying disease. Non-allergic rhinitis (NAR): negative allergy testing, triggered by non-allergic stimuli (weather changes, irritants, cold air, exercise). Subtype: vasomotor rhinitis (autonomic dysfunction). Treatment: intranasal ipratropium (anticholinergic — reduces rhinorrhea), INS, and nasal saline irrigation — no antihistamine benefit in pure NAR. INAC (intranasal antihistamine, azelastine) is effective for NAR and combined allergic-nonallergic rhinitis.
Nasal Polyps and the Dupilumab Revolution
Chronic rhinosinusitis with nasal polyps (CRSwNP): type 2 inflammatory eosinophilic condition associated with asthma (50%) and aspirin-exacerbated respiratory disease (AERD, 10%). Traditional treatment: INS plus saline irrigation (modest benefit), oral corticosteroids (limited by systemic side effects), and endoscopic sinus surgery (ESS) — effective but ~60% recurrence at 3 years. Dupilumab (IL-4Rα blockade — inhibits IL-4 and IL-13): SINUS-52 trial (NEJM 2019): dupilumab significantly reduced nasal polyp score, nasal congestion, and need for surgery (44% vs. 21% needing systemic steroids or surgery at 52 weeks vs. placebo). FDA-approved for CRSwNP and transforming the management of refractory polyps — the first biologic approved for upper airway eosinophilic disease. The nasal-sleep connection: nasal obstruction dramatically increases upper airway resistance during sleep, worsening sleep-disordered breathing and contributing to sleep fragmentation independent of OSA. Adequate rhinitis treatment reduces CPAP pressure requirements in OSA patients and improves CPAP adherence. For clinical ENT and pulmonology practices, our diagnostic equipment section includes pulse oximeters and sleep monitoring supplies relevant to nasal airway assessment and sleep-disordered breathing evaluation.
